Drug Details
| General Information of the Drug (ID: DR7548) | ||||
|---|---|---|---|---|
| Name |
Bleomycin
|
|||
| Synonyms |
bleomycin; Bleocin; Bleomicin; bleomycin a2; Bleomycine [INN-French]; Bleomycinum [INN-Latin]; Bleomicina [INN-Spanish]; Bleomycins; 11056-06-7; Bleomycin sulfate; Bleomicina; Bleomycine; Bleomycinum; Bleomycin [INN]; CCRIS 2754; HSDB 3208; NDC 0015-3010; Bleomycin [INN:BAN]; BLM; NSC 125066; SCHEMBL21090952; LMPK14000006; DB00290
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Hodgkin lymphoma [ICD-11: 2B30] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C55H84N17O21S3+
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
|
|||
| InChI |
1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
|
|||
| InChIKey |
OYVAGSVQBOHSSS-WXFSZRTFSA-O
|
|||
| CAS Number |
CAS 11056-06-7
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Honokiol | Magnolia officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Activity | POLB | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Activity | POLL | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| UACC-903 | CVCL_4052 | Cutaneous melanoma | Homo sapiens | |||
| Experimental
Result(s) |
Honokiol inhibits DNA polymerases Beta and Lambda and increases Bleomycin sensitivity of human cancer cells. | |||||
| Vinblastine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Experimental
Result(s) |
The combination of vinblastine and bleomycin achieved a high rate of objective responses in a subgroup of elderly and symptomatic patients, without considerable toxicity. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Molecule Info | [4] | |
